Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome

Amselem, Luis; Montero, Javier A.; Díaz-Llópis, Manuel; Pulido, José S.; Bakri, Sophie J.; Palomares, P.; García-Delpech, S.

doi:10.1016/j.ajo.2007.02.037

Cited by 42 publications

(29 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several case reports also demonstrate bevacizumab as a treatment option for neovascular glaucoma secondary to central retinal venous occlusion, central retinal artery occlusion or proliferative diabetic retinopathy [2, 3]. Additionally, the use of intravitreal injection of bevacizumab in ocular ischemic syndrome (OIS) showed encouraging results in one report [4]. However, these ocular usages are not formulated, and bevacizumab has only been approved by the Food and Drug Administration for oncology indications [5].…”

Section: Introductionmentioning

confidence: 99%

Acute Vision Loss after Intravitreal Injection of Bevacizumab (Avastin) Associated with Ocular Ischemic Syndrome

et al. 2009

View full text Add to dashboard Cite

Aim: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab. Methods: A 55-year-old man had diabetes with unilateral rubeosis and macular edema. Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness. A complete ocular examination, fluorescein angiography, carotid artery Doppler sonography and brain magnetic resonance imaging were performed. Results: Best corrected visual acuity before injection was 6/60 in the left eye. He had underlying left carotid artery stenosis combined with bilateral preproliferative diabetic retinopathy. Three days after intravitreal injection of bevacizumab, acute ocular ischemic syndrome occurred. He also suffered from acute stroke, and brain magnetic resonance angiography showed total left internal carotid artery occlusion. The final visual acuity was no light perception in the left eye and 3/6 in the right eye. Conclusions: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus. Acute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery.

show abstract

Section: Introductionmentioning

confidence: 99%

Acute Vision Loss after Intravitreal Injection of Bevacizumab (Avastin) Associated with Ocular Ischemic Syndrome

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Therefore, in the cases where there is retinal ischemia, prophylactic PRP is advisable. Neovascularization and macular edema caused by OIS can be also treated with intravitreal bevacizumab (Amselem et al, 2007). In this case report neovascularization regressed, but there was no improvement in VA or IOP.…”

Section: Managementmentioning

confidence: 82%

Retinal Vascular Occlusions

Bradvica¹,

Benašić²,

Vinković³

2012

Advances in Ophthalmology

View full text Add to dashboard Cite

“…There are only a few case reports of intraocular injections of anti-VEGF agents in patients with ocular ischemic syndrome [21,26,27]. Among four cases presented in these reports, one case demonstrated vision loss, retinal vessel constriction and a profound decrease in the area of retinal perfusion 2 weeks after intravitreal ranibizumab injection [21].…”

Section: Discussionmentioning

confidence: 96%

Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

Higashide

Murotani

Saito

et al. 2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Central retinal artery occlusion may be a relatively common complication following intraocular injection of anti-VEGF agents in patients with neovascular glaucoma, particularly when it was associated with ocular ischemic syndrome. Since visual prognosis of central retinal artery occlusions is usually poor, intraocular injection of anti-VEGF agents should be performed with thoughtful consideration of the risks and benefits of the treatment, and with a strict follow-up examination, especially in high-risk patients.

show abstract

Intravitreal Bevacizumab (Avastin) Injection in Ocular Ischemic Syndrome

Cited by 42 publications

References 4 publications

Acute Vision Loss after Intravitreal Injection of Bevacizumab (Avastin) Associated with Ocular Ischemic Syndrome

Acute Vision Loss after Intravitreal Injection of Bevacizumab (Avastin) Associated with Ocular Ischemic Syndrome

Retinal Vascular Occlusions

Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma

Contact Info

Product

Resources

About